CE Mark approval obtained

Article

STAAR Surgical has announced that its Visian Implantable Collamer Lens (ICL) V4c design has obtained CE Mark approval.

STAAR Surgical has announced that its Visian Implantable Collamer Lens (ICL) V4c design has obtained CE Mark approval.

The lens design incorporates a proprietary port in the centre of the ICL optic of a specific size that the company reports optimizes fluid flow within the eye and can eliminate the need for a surgeon to perform a YAG peripheral iridotomy procedure before implantation.

Clinical research on this technology has been performed by Dr Kimiya Shimizu, professor and chair of the Department of Ophthalmology at the Kitasato University in Tokyo, Japan. He started performing first phase trials in 2008 when he implanted six patients with the current ICL in one eye and the new V4c design in the fellow eye. Dr Shimizu performed iridotomies in the eyes implanted with the current ICL and not in the eyes with the new V4c design lens.

He continued his research performing the second phase study in 2010 using the same clinical protocol as before. He found that the post-op IOP of the fellow eyes was the same as the eyes with the current ICL model. Additionally, he evaluated other parameters such as visual acuity, contrast sensitivity, stability of refraction and visual disturbances and found similar results with the new design as have been achieved with the current model.

The V4c model has been approved in the -0.5 to -18.0 D myopic range and +0.5 cylinder power to +6.0 for the Toric ICL models.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.